Treatment with dexamethasone and monophosphoryl lipid A removes disease-associated transcriptional signatures in monocyte-derived dendritic cells from rheumatoid arthritis patients and confers tolerogenic features

Treatment with dexamethasone and monophosphoryl lipid A removes disease-associated transcriptional signatures in monocyte-derived dendritic cells from rheumatoid arthritis patients and confers tolerogenic features

Tolerogenic dendritic cells (TolDCs) are promising tools for therapy of autoimmune diseases such as rheumatoid arthritis (RA). Here we characterise monocyte-derived TolDCs from RA patients modulated with dexamethasone and activated with monophosphoryl lipid A (MPLA), referred to as MPLA-tDCs, in ter...

Full description

Bibliographic Details
Main Authors: Paulina Andrea García-González, Katina Schinnerling, Alejandro Sepúlveda-Gutiérrez, Jaxaira Maggi, Lorena Hoyos, Rodrigo A Morales, Ahmed M Medhi, Hendrik J Nel, Lilian Soto, Bárbara Pesce, María Carmen Molina, Miguel Cuchacovich, Milton Larrondo, Oscar Neira, Diego Francisco Catalán, Catharien Hilkens, Ranjeny Thomas, Ricardo A Verdugo, Juan C Aguillon
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-10-01
Series:Frontiers in Immunology
Subjects:
Immune Tolerance
Transcriptome
Rheumatoid arthritis
Tolerogenic dendritic cells
cell-based therapy
Online Access:http://journal.frontiersin.org/Journal/10.3389/fimmu.2016.00458/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fimmu.2016.00458/full

Similar Items